{"created":"2023-05-15T14:53:56.191692+00:00","id":73442,"links":{},"metadata":{"_buckets":{"deposit":"15c0eff9-9034-4cec-9457-5cfffa76e0ac"},"_deposit":{"created_by":1,"id":"73442","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"73442"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00073442","sets":["1"]},"author_link":["771896","771898","771895","771894","771899","771901","771900","771897"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-07","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"87","bibliographicPageStart":"77","bibliographicVolumeNumber":"55","bibliographic_titles":[{"bibliographic_title":"核医学"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"要旨：放射性Cu-ATSM［Cu-diacetyl-bis （N 4-methylthiosemicarbazone）］は，放射性Cu がキレートであるATSM に配位した構造をとる低分子化合物であり，がんの低酸素領域に集積性を示すPET 用放射性薬剤として開発された．中でも，放射性64Cu は，陽電子の他に，細胞に障害を与えるβ－線・オージェ電子を放出するため，64Cu-ATSM はPET 診断目的のみならず，内用療法用薬剤として期待されている．特に，悪性脳腫瘍に対しては，PET 臨床試験においてCu-ATSM が高集積することが示されている他，非臨床試験においても64Cu-ATSM 治療により高い薬効が得られることが報告されている．こうした知見に基づき，放射性薬剤64Cu-ATSM を用いた内用療法の臨床開発が期待される．そこで，今後実施が計画される臨床研究に先立ち，本稿では，放射性薬剤64Cu-ATSM を用いた内用療法における退出基準ならびに病室に係る基準につき放射線防護の観点から検討した．","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"一般社団法人 日本核医学会"}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.18893/kakuigaku.tr.1801","subitem_relation_type_select":"DOI"}}]},"item_8_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/article/kakuigaku/55/1/55_tr.1801/_article/-char/ja/","subitem_relation_type_select":"URI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2189-9932","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"吉井, 幸恵"}],"nameIdentifiers":[{"nameIdentifier":"771894","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉本, 光喜"}],"nameIdentifiers":[{"nameIdentifier":"771895","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"東, 達也"}],"nameIdentifiers":[{"nameIdentifier":"771896","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"細野, 眞"}],"nameIdentifiers":[{"nameIdentifier":"771897","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshii, Yukie","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"771898","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshimoto, Mitsuyoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"771899","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"771900","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hosono, Makoto","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"771901","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"放射性薬剤64Cu-ATSM による内用療法における退出基準・病室に係る基準に関する検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"放射性薬剤64Cu-ATSM による内用療法における退出基準・病室に係る基準に関する検討"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-02-25"},"publish_date":"2019-02-25","publish_status":"0","recid":"73442","relation_version_is_last":true,"title":["放射性薬剤64Cu-ATSM による内用療法における退出基準・病室に係る基準に関する検討"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-16T00:27:02.753270+00:00"}